Adagene Spon Ads Each Rep 1.25 Ord Shs (ADAG) Stock
Biotech firm developing antibodies for cancer and immune therapies. Here's the price, business snapshot, and what's worth knowing about Adagene Spon Ads Each Rep 1.25 Ord Shs in August 2026.
Adagene Inc-ADR (ADAG) is a small-cap, clinical-stage biotechnology company focused on antibody discovery and engineering to develop immuno‑oncology and immune-modulating therapies. Listed as an American Depositary Receipt, it combines research platforms with collaborations to advance therapeutic candidates from preclinical studies into clinical trials. With a market capitalisation around $89.08 million, Adagene is at an early development stage: its value is driven mainly by pipeline progress, partnership deals and trial data rather than steady revenues. Investing in clinical-stage biotech carries heightened risks — programmes can fail, dilutive financing may be needed and share price volatility is common. For investors, it’s useful to monitor trial milestones, cash runway, partnership announcements and regulatory updates. This summary is for general educational purposes only and is not personalised investment advice; investors should consider their risk tolerance and consult a financial professional before making investment decisions.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Adagene stock with a target price of $5.5, indicating good growth potential.
Financial Health
Adagene is struggling to generate significant revenue and has limited financial resources.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Pipeline Milestones Matter
Clinical trial readouts, INDs and partnership deals can drive revaluation, though outcomes are uncertain and timing may be unpredictable.
Collaborations and Partners
Licensing and alliances can de‑risk programmes and provide funding, but agreements vary and may affect long‑term upside.
Small‑Cap Volatility
With a sub‑$100M market cap, shares can swing sharply on news; this may suit risk‑tolerant investors but carries higher downside.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
